Alumis To Merge With Acelyrin, But Pause Lonigutamab Program
Alumis said it will pause the planned Phase III program for Acelyrin’s lead drug and assess the value of the candidate, which produced underwhelming Phase II results in January.
Alumis said it will pause the planned Phase III program for Acelyrin’s lead drug and assess the value of the candidate, which produced underwhelming Phase II results in January.